ChinaBio® Group

Helping western life science companies achieve success in China.

[ChinaBio® Group @ChinaBio]

Week In Review: CanSino Nears $1 Billion Valuation Following Hong Kong IPO $AZN $MDT $ORMP https://t.co/xc1Unlv7ZV

[ChinaBio® Group @ChinaBio]

Week In Review: Tianjin CanSino Staging $160.5 Million Hong Kong IPO $MRK https://t.co/NakRBJr5rc

[ChinaBio® Group @ChinaBio]

Week In Review: Grifols Pays $1.9 Billion For 26% Stake In Shanghai RAAS $CASI $BGNE $GRFS $NVO https://t.co/rf0rbGpcBR

[ChinaBio® Group @ChinaBio]

Week In Review: Nanjing's NJCTTQ Agrees To $4 Billion Package For Abpro Bi-Specific Immunotherapies $ASLN $BCAC https://t.co/YKQB33roae

[ChinaBio® Group @ChinaBio]

Week In Review: Sciwind, A Hangzhou Biopharma, Raises $29.5 Million For NASH Treatments https://t.co/ZUsG7gXpt3

[ChinaBio® Group @ChinaBio]

Week In Review: New Shanghai Hi-Tech Exchange To IPO Pre-Revenue Companies https://t.co/iT2LDGqyGt

[ChinaBio® Group @ChinaBio]

Week In Review: China Green Lights Nasdaq-Style Exchange For Young Companies $CIR $BABA $KANG $TCON https://t.co/BuSpeVe3jP

[ChinaBio® Group @ChinaBio]

Week In Review: Yantai's MabPlex Raises $59 Million To Expand CDMO Services $AZN $IRWD $CBMG $BGNE https://t.co/NWU5BAPlTw

[ChinaBio® Group @ChinaBio]

Week In Review: China Life Science Starts Off 2019 With $425 Million In Deals $NVS $SPRO $CBMG $BHVN $ASLN https://t.co/wrvjLSxD4S

[ChinaBio® Group @ChinaBio]

Week In Review: 2018 Results: China Life Science Investment Hits Record Levels $NVCR $ATNX $ZLAB https://t.co/tKbi74c7f6

[ChinaBio® Group @ChinaBio]

Week In Review: Shanghai Industrial To Start $7.3 Billion Biomedical Fund In 2019 $AZN $LLY $FGEN https://t.co/1wOWlatcrc

[ChinaBio® Group @ChinaBio]

Week In Review: Two China Biopharmas Raise $1.4 Billion In Hong Kong IPOs $ZLAB https://t.co/W0MmLTHyN7

[ChinaBio® Group @ChinaBio]

Week In Review: China Pharmas Announce Deals Worth $1.5 Billion $RVNC $VBIV $CASI $SPPI https://t.co/6LsV9i6kEb

[ChinaBio® Group @ChinaBio]

Week In Review: BeiGene Forges $1.3 Billion Bi-Specific Antibody Deal With Zymeworks $LLY $HCM $BGNE $MGNX $ZLAB https://t.co/5g2jqZBC9P

[ChinaBio® Group @ChinaBio]

Week In Review: Alphamab Closes $100 Million Series A For Oncology Candidates $LLY $CASI $BIIB $GILD https://t.co/kq9XVmmwzj

[ChinaBio® Group @ChinaBio]

Week In Review: CStone Pharma, A Suzhou Oncology Company, Files For Hong Kong IPO $A $CUE https://t.co/jh5wPQQwe9

[ChinaBio® Group @ChinaBio]

Week In Review: Innovent Completes $421 Million Hong Kong IPO; Will Start Trading Next Week $CASI $ZLAB https://t.co/xz6VHtRHXk

[ChinaBio® Group @ChinaBio]

Week In Review: Innovent's Hong Kong IPO: Raising $422 Million At $2 Billion Valuation $LLY $APDN $CGIX $HCM https://t.co/YskLSpwt66

[ChinaBio® Group @ChinaBio]

Week In Review: Biosense Exercises $75 Million Option For China Rights To Neovacs' Lupus Immunotherapy $MEIP $BGNE https://t.co/74UPbst1ty

[ChinaBio® Group @ChinaBio]

Week In Review: Shanghai Henlius To File For Hong Kong IPO At Valuation Of Over $1 Billion $GILD $CBMG https://t.co/gJ2Jggkfgw